Goldman Sachs
CLDX icon

Goldman Sachs’s Celldex Therapeutics CLDX Stock Holding History

Goldman Sachs’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-25,200
Closed -$637K – 6105
2024
Q4 		$637K Hold
25,200
– – ﹤0.01% 5107
2024
Q3 		$857K Hold
25,200
– – ﹤0.01% 4743
2024
Q2 		$933K Hold
25,200
– – ﹤0.01% 4453
2024
Q1 		$1.06M Hold
25,200
– – ﹤0.01% 4317
2023
Q4 		$999K Buy
+25,200
New +$741K ﹤0.01% 4386
2015
Q3 		– Sell
-10,000
Closed -$3.78M – 7290
2015
Q2 		$3.78M Buy
+10,000
New +$3.97M ﹤0.01% 3199

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs's CLDX Position: Q2 2026 in Review

Goldman Sachs increased its Celldex Therapeutics (CLDX) stake by 63% in Q2 2026, buying an estimated $20.2M and bringing the position to 1,615,343 shares worth $60.1M. The position accounts for 0.01% of the portfolio, ranked #1654.

Goldman Sachs first reported a position in CLDX in Q2 2013 and has held it in 47 quarters since. The position peaked at $62.4M in Q3 2024. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Goldman Sachs held 1,615,343 shares of Celldex Therapeutics worth $60.1M as of Q2 2026.
  • Goldman Sachs bought 626,927 Celldex Therapeutics shares in Q2 2026, an estimated $20.2M.
  • Celldex Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1654 holding.
  • Goldman Sachs first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 47 quarters since.
  • Goldman Sachs's Celldex Therapeutics position peaked at $62.4M in Q3 2024.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.